Cellular and Molecular Therapeutics Laboratory, Centre for Biomaterials, Cellular and Molecular Theranostics (CBCMT), Vellore Institute of Technology (VIT), Vellore, TN, 632014, India.
Centre for Biomaterials, Cellular and Molecular Theranostics (CBCMT), Vellore Institute of Technology (VIT), Vellore, TN, India.
Cell Tissue Res. 2019 Aug;377(2):125-151. doi: 10.1007/s00441-019-03039-1. Epub 2019 May 7.
Axonal regeneration and formation of tripartite (axo-glial) junctions at damaged sites is a prerequisite for early repair of injured spinal cord. Transplantation of stem cells at such sites of damage which can generate both neuronal and glial population has gained impact in terms of recuperation upon infliction with spinal cord injury. In spite of the fact that a copious number of pre-clinical studies using different stem/progenitor cells have shown promising results at acute and subacute stages, at the chronic stages of injury their recovery rates have shown a drastic decline. Therefore, developing novel therapeutic strategies are the need of the hour in order to assuage secondary morbidity and effectuate improvement of the spinal cord injury (SCI)-afflicted patients' quality of life. The present review aims at providing an overview of the current treatment strategies and also gives an insight into the potential cell-based therapies for the treatment of SCI.
轴突再生和损伤部位三部分（轴突-胶质）连接的形成是早期修复损伤脊髓的前提。在损伤部位移植能够产生神经元和神经胶质群体的干细胞，在脊髓损伤后恢复方面取得了显著的效果。尽管大量的临床前研究使用不同的干细胞/祖细胞在急性和亚急性阶段显示出有希望的结果，但在损伤的慢性阶段，它们的恢复率显示出急剧下降。因此，开发新的治疗策略是当前的迫切需要，以减轻继发性发病率，并改善脊髓损伤（SCI）患者的生活质量。本综述旨在提供当前治疗策略的概述，并深入了解用于治疗 SCI 的潜在基于细胞的治疗方法。
